Company invests $26m in sterile Pharmaceutical Development Services suite
Patheon, global provider of drug development and delivery solutions, has completed an expansion project at its manufacturing site in Greenville, North Carolina (USA).
The company invested approximately $26m to update one of its sterile Pharmaceutical Development Services (PDS) suites and to build a fully integrated sterile PDS suite which are compliant with regulatory authorities. The PDS Suites 1 and 2 provide 7,000sqft in GMP steriles manufacturing space.
The newly built PDS suite will manufacture sterile liquid and lyophilised drug products. It features freeze dryers and a fully integrated filling line fitted with a Restricted Access Barrier System (RABS) for sterile drug products.
The company has made the investment in disposable manufacturing in this suite eliminating the need for cleaning verification for liquid filling, reducing set up time/product losses and enhancing sterility assurance.
This suite is fully integrated and designed for products in clinical development with the ability to scale up to much larger batch sizes.
Patheonís Greenville manufacturing site is a large, multi-purpose pharmaceutical manufacturing and packaging campus.
The facility provides both solid dose form manufacturing/packaging and sterile dose manufacturing, filling and lyophilisation of both biopharmaceuticals and small molecules.
Another development in Greenville is the installation of a continuous manufacturing suite.